The purpose of this study is to identify novel biomarkers in the early stage of Type 1 Diabetes as well as to follow disease progression in individuals with early onset T1D.

To be enrolled in this study, you must meet certain requirements. You may be eligible to participate if you meet the following criteria:

• Between the ages of 12-18
• Diagnosed with Type 1 Diabetes within 3 months of Screening

Study Duration: Up to 6 months

Study Commitment:

• Participants with Type 1 Diabetes:  3 separate visits to the AdventHealth Translational Research Institute
• Participants without Type 1 Diabetes:  1 visit to the AdventHealth Translational Research Institute

Study Procedures:

• Vital signs, height, weight
• Fasting Blood draw
• Glucose-Insulin log

Compensation: Up to $50 for participants without diabetes. Up to 150 for participants with type  diabetes

Study Contact: To learn more, please call 1-877-854-8475 or fill out the Contact us form.

This study is being conducted under the direction of Richard E. Pratley, MD at 301 East Princeton Street, Orlando, Florida 32804.